DENTSPLY SIRONA (XRAY) and PDS Health recently reported completion of more than five million CEREC chairside restorations across more than 1,200 systems, highlighting the broad use of digital workflows that support same-day treatment and more efficient dental practices.

Alongside the CEREC milestone, DENTSPLY SIRONA has seen a 17.91% 1 month share price return and a 3.37% year to date share price return, although its 1 year total shareholder return has declined 28.17%. This points to positive near term momentum on a still weak long term track record.

If you are looking beyond DENTSPLY SIRONA in healthcare technology, this could be a good moment to scan for other digital health opportunities through the 40 healthcare AI stocks.

With DENTSPLY SIRONA shares up over the past month but still carrying a weak multi year shareholder record and trading below some valuation estimates, the key question is whether this is a reset that is pricing in all the bad news or a starting point for future growth that is being underappreciated by the market.

Most Popular Narrative: 74.4% Undervalued

The most followed narrative on DENTSPLY SIRONA compares a fair value of $45.50 to the recent $11.65 share price, framing the stock as deeply discounted while still anchored in the economics of dental practices and long equipment cycles.

Dentsply Sirona is built for endurance. Its business model mirrors the dental industry itself: methodical, relationship driven, and anchored in necessity. For investors, XRAY represents exposure to healthcare demand that persists across cycles. It may never dominate headlines, but its relevance is quietly reinforced every time a patient sits in a dental chair.

Want to see how that long term endurance story turns into a $45.50 fair value? The narrative leans on steady demand assumptions, margin rebuild, and a future earnings multiple usually associated with higher quality compounders. Curious which revenue glide path and profitability reset sit underneath those inputs? The full narrative lays out the numbers and joins them back to real world dental practice behavior.

Result: Fair Value of $45.50 (UNDERVALUED)

However, DENTSPLY SIRONA’s recent net income loss of $628 million and a 3 year total shareholder return that declined 67.45% both challenge the durability story that investors are weighing.

Next Steps

With sentiment on DENTSPLY SIRONA clearly divided, this is a good time to review the data yourself and pressure test the bullish points that investors are focused on through the 3 key rewards.

Looking for more investment ideas beyond DENTSPLY SIRONA?

If DENTSPLY SIRONA has sharpened your focus on healthcare, do not stop there. Smarter decisions can come from comparing a few well chosen opportunities side by side.

• Spot potential bargains early by scanning companies that screen as attractively priced using the 44 high quality undervalued stocks.
• Prioritise resilience by reviewing stocks highlighted in the 74 resilient stocks with low risk scores to see which businesses carry lower overall risk scores.
• Get ahead of the crowd by checking the screener containing 18 high quality undiscovered gems before others focus on those fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.